FY2029 EPS Forecast for Kura Oncology Decreased by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Brookline Capital Markets cut their FY2029 earnings per share (EPS) estimates for shares of Kura Oncology in a research note issued on Tuesday, November 10th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings per share of $5.59 for the year, down from their previous forecast of $5.70. The consensus estimate for Kura Oncology’s current full-year earnings is ($3.25) per share. Brookline Capital Markets also issued estimates for Kura Oncology’s FY2030 earnings at $17.45 EPS.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.04. Kura Oncology had a negative return on equity of 265.89% and a negative net margin of 369.26%. The business had revenue of $22.84 million for the quarter, compared to the consensus estimate of $24.94 million.

A number of other research analysts have also weighed in on KURA. Raymond James Financial set a $24.00 target price on shares of Kura Oncology in a report on Monday, August 24th. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a research note on Monday, August 24th. UBS Group reiterated a “buy” rating on shares of Kura Oncology in a research report on Monday, October 5th. Morgan Stanley set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, October 15th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.35.

Kura Oncology Stock Up 2.1%

Shares of KURA opened at $7.73 on Thursday. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. Kura Oncology has a 1 year low of $6.75 and a 1 year high of $13.90. The business’s 50 day simple moving average is $10.39 and its 200-day simple moving average is $9.78.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 28,802 shares of the stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total transaction of $309,621.50. Following the transaction, the insider directly owned 141,095 shares in the company, valued at $1,516,771.25. This represents a 16.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Teresa Bair sold 8,442 shares of the firm’s stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $10.50, for a total transaction of $88,641.00. Following the transaction, the insider directly owned 187,002 shares in the company, valued at $1,963,521. This trade represents a 4.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 153,881 shares of company stock valued at $1,708,183 over the last three months. 7.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of the business. IFP Advisors Inc lifted its position in shares of Kura Oncology by 136.5% in the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after purchasing an additional 1,467 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Kura Oncology by 14.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,232 shares of the company’s stock valued at $175,000 after buying an additional 2,104 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in Kura Oncology by 11.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 23,297 shares of the company’s stock valued at $194,000 after buying an additional 2,304 shares during the period. Sterling Capital Management LLC increased its holdings in Kura Oncology by 842.5% during the third quarter. Sterling Capital Management LLC now owns 2,818 shares of the company’s stock valued at $30,000 after buying an additional 2,519 shares during the period. Finally, Pictet Asset Management Holding SA raised its stake in Kura Oncology by 22.6% in the third quarter. Pictet Asset Management Holding SA now owns 14,412 shares of the company’s stock worth $154,000 after buying an additional 2,656 shares in the last quarter.

About Kura Oncology

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.